Suchergebnisse - "Kanhai, Karan"

PubPharm (15)

1

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

enthalten in: bioRxiv.org | 2024

von Gritti, G. | Raimondi, F. | Ripamonti, D. | +18

2

Correction to : Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis

enthalten in: Leukemia | 2023

von Mukherjee, S. | Kanhai, K. | Kauffman, D. | +6

ErratumFor: Leukemia. 2022 Oct;36(10):2539-2543. - PMID 36175555

3

Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease : a population-level US health claims analysis

enthalten in: Leukemia | 2022

von Mukherjee, S. | Kanhai, K. | Kauffman, D. | +6

ErratumIn: Leukemia. 2023 Jan;37(1):253. - PMID 36526737

4

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

enthalten in: Blood advances | 2022

von van Rhee, F. | Rosenthal, A. | Kanhai, K. | +4

5

The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry

enthalten in: British journal of haematology | 2022

von Fajgenbaum, D. | Pierson, S. | Kanhai, K. | +8

6

Optimisation of anti-interleukin-6 therapy : Precision medicine through mathematical modelling

enthalten in: Frontiers in immunology | 2022

von Rossi, J. | Chiang, H. | Lu, Z. | +5

7

The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry

enthalten in: British Journal of Haematology | 2022

von Fajgenbaum, D. | Pierson, S. | Kanhai, K. | +7

8

Correction : Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

enthalten in: Leukemia | 2021

von Gritti, G. | Raimondi, F. | Bottazzi, B. | +19

ErratumFor: Leukemia. 2021 Sep;35(9):2710-2714. - PMID 34031531

9

Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

enthalten in: Leukemia | 2021

von Gritti, G. | Raimondi, F. | Bottazzi, B. | +19

ErratumIn: Leukemia. 2021 Jun 28;:. - PMID 34183767

10

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease : a prespecified, open-label, extension analysis of two trials

enthalten in: The Lancet. Haematology | 2020

von van Rhee, F. | Casper, C. | Voorhees, P. | +4